Targeting Melanoma

Written on |

TAU researchers create a nanocarrier that selectively delivers two medications and releases them simultaneously at the malignant target

Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro from the Department of Physiology and Pharmacology at the  Sackler Faculty of Medicine, developed an innovative nanotechnological drug delivery system that significantly enhances the effectiveness of treatment for the aggressive skin cancer melanoma. The nanocarrier is a biocompatible and biodegradable polymer, which comprises repeating units of glutamic acids (PGA- polyglutamic acid), packaging together two biological drugs belonging to different families with proven efficacy for the treatment of melanoma: BRAF inhibitors (Dabrafenib) and MEK inhibitors (Selumetinib, approved for use in children with NF1 – neurofibromatosis type I).

Prof. Satchi-Fainaro: “One of the major obstacles of the biological treatments is that after a while, the cancer cells develop resistance to the drugs. We assume that by precise delivery of two or more targeted drugs that will attack the cancer cells forcefully and simultaneously from different directions, we can delay or even prevent the acquisition of this drug-resistance.”

The research group included PhD students Evgeni Pisarevsky, Dr. Rachel Blau and Yana Epshtein from Prof. Satchi-Fainaro’s research laboratory at TAU’s Sackler School of Medicine. The paper was published as the cover article of the August 2020 issue of Advanced Therapeutics.

Prof. Satchi-Fainaro: “In this project, we looked for a solution to a problem often associated with drug cocktails: Today, most oncological treatments are administered in the form of cocktails of several medications; However, despite the fact that all drugs are administered to the patient simultaneously, they do not reach the tumor at the same time, due to differences in basic parameters – like how long they survive in the bloodstream (i.e. half-life), and the time it takes each drug to reach the tumor tissue. Thus, in most cases, the medications do not work concurrently, which prevents them from attaining optimal synergistic activity.”

Responding to these challenges, the researchers developed an innovative, efficient and biodegradable drug delivery system. Two biological drugs, known to be effective for the treatment of melanoma, Dabrafenib and Selumetinib, (inhibiting two different components – BRAF and MEK respectively – in the biological pathway which is over-activated in melanoma), were chosen, with the intention of delivering them jointly to the tumor by using a nanocarrier. The drug nanocarrier chosen for the task was PGA, a polymer of glutamic acid – one of nature’s most common amino acids. Developed in Prof. Satchi-Fainaro’s lab several years ago, the nanocarrier has already been tested successfully for treating pancreatic, breast and ovarian cancer in animal models.

In search of an optimal ratio

First, the researchers determined the optimal ratio between the two medications – based on levels and types of toxicity, as well as the resistance mechanism developed by cancer cells for each medication – to ultimately ensure maximum effectiveness, minimal toxicity and optimal synergistic activity. Another important advantage of joint delivery is reduced dosage: a much lower dose is required compared to each drug when administered independently.

The next step was using chemical modifications to enable bonding between the polymeric carrier and the chosen drugs. This combined system can travel through the body with total safety, inflicting no damage to healthy tissues. Upon reaching the cancer cells, the nanocarrier encounters proteins of the cathepsins enzyme family, which are highly activated in malignant tumors. The proteins degrade the polymer, releasing the drugs which become active and join forces to attack the tumor. Prof. Satchi-Fainaro: “It’s like several passengers riding in one cab and getting off together at the same address. They all arrive at the same destination, right at the same time.”

Promising results

Tested on a mouse model of melanoma, the new treatment showed promising results: The nanocarrier delivered the two drugs to the tumor and released them there simultaneously in quantities about 20 times greater than those that reach the tumor when similar doses of the same medications are administered independently. In addition, the therapeutic effect achieved by the drugs delivered by the nanocarrier lasted much longer – 2-2.5 times compared to control group and the group treated with free medications. According to the researchers, this means that the new platform enables much lower dosages – about one third of the dose required in regular drug cocktails, and the treatment as a whole is both safer and more effective. Also, if needed, the new approach allows for dosages that are much higher than the maximum dosage permissible in current methods, thereby enhancing the effectiveness of the treatment even further.

Prof. Satchi-Fainaro: “In this project, we developed an innovative drug delivery system for treating melanoma, delivering two proven medications and releasing them simultaneously at the tumor site. The treatment proved both safer and more effective than the same medications administered as a cocktail. Moreover, our new platform is highly modular and can be used for delivering a vast range of medications. We believe that its potential for enhancing therapeutics for different diseases is practically endless.”

The study was funded by the Israel Cancer Research Fund (ICRF), the European Research Council (ERC), Israel’s Ministry of Health (EuroNanoMed-II program), the Melanoma Research Alliance, the Morris Kahn 3D BioPrinting for Cancer Research Initiative and the Israel Science Foundation (ISF).

Featured image: Prof. Ronit Satchi-Fainaro

related posts

Recruiting ‘Fighting Cells’ to Destroy Tumors

September 14, 2021

TAU Team Reverses Early Signs of Alzheimer’s

September 10, 2021

Nicotine Testing of Children Curbs Parents’ Smoking

September 5, 2021

The Silent Prophets

August 31, 2021

Want to Fall in Love? Step Outside in The Sun

August 30, 2021

First 3D-bioprinting of entire active tumor

August 18, 2021

New Warning Sign for Breast Cancer

August 6, 2021

COVID-19 Immunity Varies Among Genders and Age Groups

July 25, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

A world first: Technology that restores the sense of touch in nerves damaged as a result of amputation or injury

July 15, 2021

New nanotech from TAU produces “healthy” electric current from the human body itself

July 9, 2021

Want to Live a Long Life? Consider Investing in Your Marriage.

July 2, 2021

A world first: Targeted delivery of therapeutic RNAs only to cancer cells, with no harm caused to healthy cells

June 30, 2021

Combating Antibiotic Resistance

June 22, 2021

Diamonds in the Rough

June 3, 2021

How Will We Brave the Post-COVID Era?

May 31, 2021

Are We Getting to the Root of Cancer?

May 3, 2021

Optical Technology Generates Immediate Melanoma Diagnosis

April 27, 2021

Gut Healing

April 25, 2021

Could Your Smartphone Be Damaging Your Teeth?

April 4, 2021

The Quest for A Lifesaving Cure

March 16, 2021

A Healthier Alternative to Antibiotics

February 24, 2021

Children with Autism during Lockdown: Serious Implications for Behavior and Development

February 22, 2021

Cancer Breakthrough: Cells’ Uniqueness is Also Weakness

January 29, 2021

TAU Scientists Develop Innovative Therapy to Prevent Deafness

December 28, 2020

Two TAU Professors Win 2020 Nature Mentoring Award

December 28, 2020

Lack of Teacher Support during Pandemic Causes Acute Emotional Harm

December 4, 2020

New Discovery: Development of the Inner Ear in Embryos is Similar to Crystal Formation

November 26, 2020

In First, Aging Stopped in Humans: TAU Co-Study

November 23, 2020

TAU developed genome editing system destroys cancer cells

November 20, 2020

TAU Co-Study: “Green Revolution” Decreased Infant Mortality

November 17, 2020

Study: Women Suffer More from COVID-related Orofacial Pain

November 12, 2020

Global First: Center for Combating Pandemics

October 22, 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

October 12, 2020

Researchers Identified the Genetic Causes of Inherited Hearing Loss in the Jewish Population of Israel

September 30, 2020

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

September 8, 2020

Physical exercise can help improve both physical and mental health

August 31, 2020

New school for Biomedicine and Cancer Research at Tel Aviv University

August 13, 2020

An Experimental Drug for Alzheimer’s May Help Children with Autism

August 5, 2020

TAU Study: Stimulating Immune System Prevents Post-Surgery Metastasis

July 27, 2020

TAU Researcher Fights Epidemics Both Viral and Virtual

July 23, 2020

TAU study: Oxygen therapy improves cognitive function in seniors

July 16, 2020

TAU-led Team Destroys Cancer Cells with Ultrasound

July 9, 2020

New nanomedicines for mRNA therapeutics in breast cancer and heart failure

July 6, 2020

3D printed heart used to test life-saving drugs

June 29, 2020

Did climate change cause infections 6,000 years ago?

May 21, 2020

Accurate 3D imaging could significantly improve IVF treatments

May 18, 2020

TAU study finds widespread misinterpretation of gene expression data

December 26, 2019

Fibroblasts involved in healing spur tumor growth in cancer

December 23, 2019

Eating in sync with biological clock could replace diabetes treatment

December 15, 2019
Ontario and Western Canada

3130 Bathurst Street, Suite, 214, Toronto, ON | M6A 2A1 
Phone: 416.787.9930 | Toll Free: 833.32.CFTAU (22328)
Email: toronto@cftau.ca

Ottawa, Quebec and Atlantic Canada

6900 Boulevard Décarie, Suite 3480, Montreal, QC | H3X 2T8
Phone: 514.344.3417
Email: montreal@cftau.ca


© CFTAU  | all rights reserved
Charitable registration: 124035643RR0001

TO TOP